Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

Key Points

• To compare the time and operational efficiency of subcutaneous versus intravenous administration of natalizumab for treating relapsing-remitting multiple sclerosis.
• Conducted a time and motion study across France, Spain, and the United Kingdom.
• Compared active healthcare provider time and patient chair time for both administration routes.
• Surveyed healthcare providers' satisfaction and preference regarding administration methods.
• Subcutaneous administration significantly reduced active healthcare provider time.
• Patient chair time was also lower for subcutaneous compared to intravenous administration.
• Healthcare providers preferred subcutaneous administration, indicating higher satisfaction.